The Clinical Trials on Alzheimer’s Disease (CTAD) conference brought together the world’s leading Alzheimer’s Disease (AD) researchers, with a major focus on the latest breakthroughs in blood-based biomarkers. These innovations are rapidly advancing our understanding of AD and paving the way for more effective diagnostics and treatments.

Our team had a wonderful time in Spain connecting with the research and diagnostic community. The data, discussions, and forward-looking vision at CTAD 2024 resulted in another successful conference with tremendous hope and promise for a brighter future in the fight against AD.

Read our CTAD 2024 highlights here.

Watch the Fireside Chat with Professor Henrik Zetterburg on Blood-Based Biomarkers

At CTAD 2024, Quanterix proudly sponsored a fireside chat with long-time collaborator, Professor Henrik Zetterberg from the University of Gothenburg. In this insightful conversation, Professor Zetterberg discussed the latest milestone discoveries in the blood-based biomarker revolution and the role of ultra-sensitive technologies in accelerating future AD advancements. 

Watch the full fireside chat below to hear Professor Zetterberg’s expert insights into the transformative potential of blood-based biomarkers for Alzheimer’s Disease research and diagnosis. 

Interested in Learning More?

Check out these additional resources on blood-based biomarkers. 

Blood Markers of Brain Health

With sensitivity up to 1000-fold greater than conventional immunoassays, Simoa® enables reliable quantification of CNS biomarkers in blood at ultra-low concentrations. The ability to measure CNS biomarkers in blood has unlocked immense new possibilities in neurology research and has the potential to fundamentally reshape brain health management. Download the brochure to learn more. 

Simoa® for Early Detection of Blood-Based Biomarkers Associated with Alzheimer’s Disease

Alzheimer‘s disease (AD) is a devastating illness that affects tens of millions of people worldwide. In addition to the emotional and financial burden on patients and caregivers, deaths from AD have doubled between 2000 and 2021, making AD the fifth leading cause of death in the population age 65 and older. This app note highlights the urgent need for more efficient detection, monitoring, and treatment methods. Download the app note to read more.

Uncover Insights with BD-Tau and Key Neurology Biomarkers

Whether your research is focused on a single neurology biomarker or spans the complex interactions of multiple markers, the Simoa® Neurology 4-Plex D (N4PD) Advantage PLUS assay delivers unmatched sensitivity, efficiency, and automated precision. With the capability to simultaneously measure NfL, GFAP, UCH-L1, and brain-derived Tau (BDTau) in both blood and cerebrospinal fluid (CSF), this assay streamlines your workflow and accelerates the discovery of critical insights for your next breakthrough. Download the flyer to learn more.